Integer Holdings Corp

Integer Holdings Corporation has entered into a definitive agreement to be acquired by affiliates of Kohlberg Kravis Roberts & Co. L.P., with each eligible share convertible into the right to receive $127 in cash at closing. The transaction, announced on Aug. 2, 2026, is not subject to a financing condition, and the buyer has obtained equity and debt financing commitments; completion remains subject to customary conditions, including approval by holders of a majority of outstanding shares and required regulatory clearances. The agreement provides for a $307 million parent termination fee in certain circumstances involving a buyer breach or failure to complete the transaction when required, and if completed, Integer Holdings would become a wholly owned subsidiary of the buyer and its shares would be delisted from the NYSE. The medical device outsourcing manufacturer, which has a market capitalization of $4.3 billion, reported mixed second-quarter 2026 results, with revenues declining 2.6% year over year to $464.1 million and adjusted earnings per share rising 3.2%. Cardio & Vascular sales fell 2% to $280.3 million on lower-than-expected adoption of two new electrophysiology products, while Cardiac Rhythm Management & Neuromodulation sales rose 1% to $173.7 million, and gross margin declined to 24.3% from 27.1% a year earlier. The Zacks Consensus Estimate for third-quarter 2026 revenues is $457.3 million, indicating a 2.2% decline from the year-ago quarter, with earnings pegged at $1.65 per share, implying a 7.8% decline.

Integer Holdings Corporation has entered a definitive agreement to be acquired by affiliates of Kohlberg Kravis Roberts & Co. L.P. in a transaction with an enterprise value of $5.7 billion. Under the deal, each eligible Integer share will be converted into the right to receive $127 in cash, without interest. The transaction requires approval by a majority of Integer's outstanding shares and applicable antitrust and foreign investment clearances, but it is not subject to a financing condition. The agreement includes a $307 million parent termination fee if Integer ends the deal under specified circumstances involving a buyer breach. Integer has withdrawn its financial outlook and canceled its second-quarter earnings call, as merger progress now takes precedence over operating targets. Second-quarter sales fell 2.6% year over year to $464.1 million, and gross margin contracted to 24.3% from 27.1%. If completed, Integer will become a wholly owned subsidiary of the buyer and its shares will be delisted from the NYSE.

Integer Holdings reported second-quarter 2026 adjusted earnings per share of $1.60, up 3.2% year over year and beating the Zacks Consensus Estimate by 15.9%. Revenue fell 2.6% to $464.1 million but still topped the consensus by 2.2%. Gross margin contracted about 280 basis points to 24.3%, and adjusted operating margin narrowed roughly 130 basis points to 15.7%. The company also announced a definitive agreement for an affiliate of KKR-managed investment funds to acquire all outstanding shares for $127 per share in cash, an enterprise value of $5.7 billion, and withdrew its previously issued financial outlook.

Eli Lilly, Novo Nordisk, and Pfizer were among the notable healthcare companies reporting quarterly results this week. Eli Lilly posted better-than-expected second-quarter results driven by its GLP-1 drugs, with revenue of $23 billion beating consensus by $2.3 billion, and raised its full-year revenue guidance to a range of $85.0 billion to $87.0 billion, though the midpoint fell short of the $85.4 billion consensus. Novo Nordisk lifted its full-year outlook for the second time this year on GLP-1 strength, now expecting sales and operating profit to decline by no more than 6% at constant exchange rates, but its U.S.-listed shares fell as much as 6%. Pfizer topped second-quarter expectations with adjusted earnings per share of $0.77 and revenue of $15.03 billion, and raised its full-year revenue guidance by $500 million at the midpoint to $60.5 billion to $62.5 billion. Merck also reported better-than-expected second-quarter results and raised its full-year revenue guidance to $66.3 billion to $67.3 billion, but lowered its adjusted earnings per share forecast to $2.66 to $2.76, below the $2.76 consensus, due to charges from its Terns acquisition. Bristol-Myers Squibb fell after a Reuters report said there are no discussions with AstraZeneca about a potential deal, contradicting earlier reports of preliminary merger talks. Integer Holdings agreed to be acquired by KKR in an all-cash deal valued at approximately $5.7 billion, with stockholders receiving $127.00 per share. The S&P 500 Health Care Index Sector gained 1.92% during the week, with Charles River Laboratories and Veeva Systems among the top gainers, while DaVita and Insulet were among the top losers.

KKR is in focus after reports that it is nearing a takeover of medical device outsourcer Integer Holdings for about $4.3 billion, with an indicated offer of $127 per share. The stock has recently shown firm short-term momentum with a 7-day share price return of 6.42% and a 30-day return of 10.09%, though the year-to-date return is down 18.04% and the one-year total shareholder return is down 26.43%. Valuation views are split: the most followed narrative on Simply Wall St sets fair value at $84.45, suggesting the stock is overvalued, while the platform's own discounted cash flow model points to a fair value of $139.01, indicating potential upside.

Simply Wall St has raised its fair value estimate for Integer Holdings to $112.14 per share, up about 15% from $97.56, following KKR's agreed all-cash offer of $127 per share. The updated model reflects slightly higher long-term revenue growth of roughly 3.87%, a future P/E multiple increase to about 25.1x, and a lower discount rate of around 7.94%. Multiple analysts downgraded the stock to neutral or equivalent ratings after the deal announcement, viewing further upside as limited and tied to deal completion. The revised fair value incorporates these shifting analyst views and deal-related assumptions.

Integer Holdings is in focus after reporting second quarter 2026 earnings and receiving a pending all-cash acquisition offer from KKR at $127 per share. The stock has surged 23.98% over the past seven days and 44.22% over 90 days, though its five-year total shareholder return stands at a more moderate 38%. On Simply Wall St's numbers, Integer trades at a price-to-earnings ratio of 29.8 times, which is below a peer average of 83.2 times but above an estimated fair P/E of 23.8 times and roughly in line with the US Medical Equipment industry average of 29 times. The company posted profit growth of 80.9% over the past year against a five-year annual earnings growth rate of 7.8%, with a net profit margin of 7.6% versus 4.5% last year, yet return on equity is considered low at 8.4% and forecast earnings and revenue growth are both described as slower than the broader US market. A discounted cash flow model suggests the $124.45 share price sits 22.3% below an estimated future cash flow value of $160.21, framing the stock as undervalued on that basis, while the P/E analysis indicates it may be about right. Deal risk remains if the KKR transaction falls through, and slower projected growth could pressure the current multiple.

KKR has agreed to acquire Integer Holdings in an all-cash transaction valued at approximately $5.7 billion. Under the definitive agreement, an affiliate of investment funds managed by KKR will purchase all outstanding shares of Integer Holdings for $127 per share in cash. The offer represents a 51.8% premium to Integer's closing price on April 29, 2026, the day before the company announced a strategic review, and a 28.8% premium to the 30-day volume-weighted average price as of July 31, 2026. Integer's board unanimously approved the deal and recommends shareholder approval, with completion expected by the end of the year subject to regulatory and shareholder approvals. Upon closing, Integer will become a privately held company and its shares will be delisted from the New York Stock Exchange.

Several major deals were reported this week across sectors. KKR is close to a deal to take medical-device outsourcer Integer Holdings private, sending its shares up 20%. Intercontinental Exchange agreed to acquire fixed-income electronic trading platform MarketAxess Holdings in a transaction valuing its equity at roughly $6.0 billion and total enterprise at $5.7 billion. Grant Thornton Advisors agreed to buy professional services firm CBIZ in an all-cash deal with a $5 billion enterprise value, backed by New Mountain Capital. Koch Inc. is exploring a sale of data center developer Edged that could value it at more than $15 billion. KKR and Energy Capital Partners agreed to acquire Ireland-based energy distributor DCC Energy in a deal valued at about £5.7 billion, with shareholders receiving £65.25 per share in cash plus a final dividend and a potential contingent payment. TransDigm Group agreed to acquire Prince & Izant from Industrial Growth Partners for approximately $1.066 billion in cash. argenx SE will acquire Forte Biosciences for $77 per share in cash, a transaction valued at roughly $2.2 billion, adding a first-in-class anti-CD122 antibody to its immunology portfolio. Ambarella shares surged 19% on a report that NXP Semiconductors is in talks to acquire the chip designer, though a deal is not certain. Curium is in advanced talks to buy radiopharma company Lantheus Holdings for about $102 per share upfront plus $12.50 per share in contingent value rights.

Integer Holdings shares surged 21% Friday afternoon following a Wall Street Journal report that private-equity firm KKR is near a deal to take the medical-device outsourcing company private. Trading in the stock was briefly halted due to volatility after the report. The deal could be announced as soon as next week and would value the Plano, Texas-based company at roughly $127 per share, according to people familiar with the matter cited by the Journal.